Biology subjects

Ackroyd, P. C.

Publications and source records attributed to Ackroyd, P. C..

3 recordsLinked to original sources

bioRxiv2025

CMG2 interaction with actin is required for growth factor-induced chemotaxis in endothelial cells.

Capillary morphogenesis gene 2 (CMG2/ANTXR2) is a cell surface receptor that contributes to corneal angiogenesis and is essential for orienting endothelial cell chemotaxis in growth factor gradients. However, the mechanism by which CMG2 transmits signals to orient endothelial cells is unknown. Here, we use affinity proteomics to identify proteins that interact with CMG2. This led us to investigate CMG2 interaction with F-actin in the context of serum and individual growth factors (bFGF/PDGF/VEGF) in both primary and immortalized endothelial cells. We also measured different matrix-protein-mediated changes in chemotaxis. We find that CMG2 function is matrix dependent, and that CMG2-actin interaction is required for serum- and growth-factor-induced chemotaxis. Inhibiting chemotaxis with CMG2 antagonists (collagen 6, penta-galloyl-glucose, or anthrax toxin protective antigen; PA) leads to the release of actin cytoskeleton from CMG2. Furthermore, CMG2 co-localizes with actin at the leading edge during live migration. This colocalization is disrupted by PA, which also disrupts directional movement. Finally, we demonstrate that the conserved actin binding domain of CMG2 directly binds to F-actin in vitro where it bundles F-actin, suggesting a mechanism by which it enables directional migration.

molecular biology↗

bioRxiv2019

Capillary morphogenesis gene 2 mediates multiple pathways of growth factor-induced angiogenesis by regulating endothelial cell chemotaxis

Pathological angiogenesis contributes to diseases as varied as cancer and corneal neovascularization. The vascular endothelial growth factor (VEGF) - VEGF receptor 2 (KDR/VEGFR2) axis has been the major target for treating pathological angiogenesis. However, VEGF-targeted therapies exhibit reduced efficacy over time, indicating that new therapeutic strategies are needed. Therefore, identifying new targets that mediate angiogenesis is of great importance. Here, we report that one of the anthrax toxin receptors, capillary morphogenesis gene 2 (ANTXR2/CMG2), plays an important role in mediating angiogenesis induced by both bFGF and VEGF. Inhibiting physiological ligand binding to CMG2 results in significant reduction of corneal neovascularization, endothelial tube formation and cell migration. We also report the novel finding that CMG2 mediates angiogenesis by regulating the direction of endothelial chemotactic migration without affecting overall cell motility.

biochemistry↗

bioRxiv2019

A canstatin-derived peptide provides insight into the role of Capillary Morphogenesis Gene 2 in angiogenic regulation and matrix uptake

Capillary Morphogenesis Gene 2 protein (CMG2) is a transmembrane, integrin-like receptor and the primary receptor for the anthrax toxin. In addition to its role as an anthrax toxin receptor, CMG2 has been repeatedly shown to play a role in angiogenic processes. However, the molecular mechanism mediating observed CMG2-related angiogenic effects has not been fully elucidated. Previous studies have found that CMG2 binds type IV collagen (Col-IV), a key component of the vascular basement membrane, as well as other ECM proteins. Currently, no link has been made between these CMG2-ECM interactions and angiogenesis; however, ECM fragments are known to play a role in regulating angiogenesis. Here, we further characterize the CMG2-Col-IV interaction and explore the effect of this interaction on angiogenesis. Using a peptide array, we observed that CMG2 preferentially binds peptide fragments of the NC1 (non-collagenous domain 1) domains of Col-IV. These domains are also known as the fragments arresten (from the 1 chain) and canstatin (from the 2 chain) and have documented antiangiogenic properties. A second peptide array was probed to map a putative binding epitope. A top hit from the initial array, a canstatin-derived peptide, binds to the CMG2 ligand-binding von Willebrand factor A (vWA) domain with sub-micromolar affinity (peptide S16, Kd = 400 {+/-} 200 nM). This peptide competes with anthrax protective antigen (PA) for CMG2 binding, and does not bind CMG2 in the presence of EDTA. Together these data suggest that, like PA, S16 interacts with CMG2 at the metal-ion dependent adhesion site (MIDAS) of its vWA domain. We demonstrate that CMG2 specifically mediates endocytic uptake of S16, since CMG2-/- endothelial cells show markedly reduced S16 uptake, without reducing total endocytosis. Furthermore, we show that S16 reduces endothelial migration but not cell proliferation. Taken together, our data demonstrate that a Col IV-derived anti-angiogenic peptide acts via CMG2, suggesting a possible link between CMG2-Col IV interactions and angiogenesis.

biochemistry↗